Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)

A trial with no phase registered on ClinicalTrials.gov. The registry status is suspended. It plans to enroll 3800 participants.

Also called NCT01305148

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Not applicable
Enrolled
  • 3,800 participants (planned count) (from the registry)
Sponsor
Iverson Genetic Diagnostics, Inc. (from the registry)
Registry
  • NCT NCT01305148
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Suspended (from the registry)

Technical summary

Registry record NCT01305148. Randomized; quadruple masking; primary purpose prevention. Start 2011-08 (registry gives no type); primary completion 2015-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Acronym
WARFARIN
Condition
Anti-coagulation Therapy
Condition
Joint Surgery Multiple
Condition
Prosthetic Replacement of Mitral Valve
Intervention (Device)
Warfarin GenoSTAT Test
Lead sponsor
Iverson Genetic Diagnostics, Inc. (class: industry)

Record details

Record id
cardio:ct-nct01305148
Content hash
a4d2779c5430c3b7bc5063ec30c7c02b079ade90c4b2b561ec8d1282c0bea929